---
title: "Panlong Pharmaceutical has received the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245261705.md"
description: "According to the Zhitong Finance APP, Panlong Pharmaceutical announced that the company recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (referred to as \"CNAS\")"
datetime: "2025-06-19T10:29:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245261705.md)
  - [en](https://longbridge.com/en/news/245261705.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245261705.md)
generator: "portal-rs"
---

# Panlong Pharmaceutical has received the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment

According to the Zhitong Finance APP, Panlong Pharmaceutical (002864.SZ) announced that the company recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (referred to as "CNAS")

### Related Stocks

- [002864.CN](https://longbridge.com/en/quote/002864.CN.md)

## Related News & Research

- [15:53 ETFoundations to Freedom Named Primary Partner of Carson Ware for the Winn-Dixie 250 at Daytona International Speedway](https://longbridge.com/en/news/296823183.md)
- [Andritz wins repeat orders from Nanning Sun Paper for China pulp and paper project](https://longbridge.com/en/news/296993005.md)
- [Subscribe for Symbiotec Pharmalab Ltd IPO; Ajcon Global](https://longbridge.com/en/news/296742246.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**